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1 Per 1,000
ortality Rate After Catheter
blation of Atrial Fibrillation
n Acceptable Risk?*
ernard Belhassen, MD
el-Aviv, Israel
atheter ablation of atrial fibrillation (AF) is increasingly
erformed in most electrophysiologic centers worldwide,
esulting in long-term arrhythmia control/cure rates 70%
1). Several randomized studies showed that ablation is
ore effective than antiarrhythmic drug therapy in patients
ith paroxysmal or persistent AF (2–5). The patients
ndergoing these procedures usually have no overt heart
isease, and their main expectations are improvement in
uality of life and functional capacity resulting from the
esumption of sinus rhythm or a significant decrease in AF
pisodes. Catheter ablation of AF is one of the most
omplex interventional procedures in medical practice. It
nvolves the introduction of multiple catheters into the
eart, transseptal catheterization, high levels of anticoagu-
ation, and delivery of multiple lesions around the pulmo-
ary vein ostia with or without additional atrial lines. The
rocedure has been associated with a minimal, but never-
heless important, risk of complications, some of them
requently lethal such as atrioesophageal fistula (6,7).
herefore, the possibility that such complications may occur
n a relatively healthy population is of great concern.
See page 1798
In a summary of a worldwide survey of 8,745 patients
181 centers) who underwent catheter ablation of AF
etween 1995 and 2002, Cappato et al. (8) reported at
east 1 major complication in 6% of the patients. The
ost significant ones were tamponade (1.2%), transient
schemic attack (0.53%), stroke (0.23%), and periproce-
ural death (0.05%). This study was limited mainly by
he diversity of the strategy of ablation used, including
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Cardiac Electrophysiology Laboratory, Department of Cardiology,o
el-Aviv Sourasky Medical Center, and Sackler School of Medicine, Tel-Aviv
niversity, Tel-Aviv, Israel.echniques that are no longer in current use such as right
trial compartmentalization and ablation of the trigger-
ng focus in 22% of patients. On the basis of results from
ingle large-volume, highly experienced centers that
howed low complication rates (9 –14), some investiga-
ors suggested that a reduction in complications rates
ould be expected with improvement of ablation tech-
ique and operator experience (15).
In this issue of the Journal, Cappato et al. (16) compiled
he results of their first survey with those of a second survey
hey conducted on patients who underwent catheter abla-
ion of AF between 2003 and 2006. The authors specifically
ooked for the frequency and cause of mortality that oc-
urred early or late after the procedure.
A total of 32,569 patients undergoing 45,115 procedures
n 262 centers reporting data safety were included in these 2
nternational surveys. Twenty-one (8%) of the 262 partici-
ating centers reported an overall mortality rate of approx-
mately 1 per 1,000 (n  32). The most frequent causes of
ortality were tamponade (n  8, 25%), stroke (n  5,
6%), and atrioesophageal fistula (n  5, 16%). The causes
f death of the remaining 14 patients were diverse. The
uthors (16) also noted that although tamponade was by far
he most frequently encountered procedure-related compli-
ation (n  331, 1%), it was responsible for fatality in only
.2% of the cases. In contrast, atrioesophageal fistula was
arely diagnosed (n  7), but it was associated with a high
ortality rate (71.4%). Stroke had an intermediate inci-
ence (n  59, 0.2%) and lethal prognosis (5.1%). Finally,
ortality was not significantly related to the volume of
blation procedures, the technique of ablation used
CARTO vs. Lasso-guided), or the type of ablation catheter
sed (irrigated/cooled tip vs. standard 4 mm).
The data reported by Cappato et al. (16) are of great
linical interest, and the authors should be congratulated
or a contribution that will certainly raise awareness in
he electrophysiologic community of the state of contem-
orary AF ablation. The large number of patients and
enters involved in this world survey suggests that a risk
f AF ablation-related mortality of 1 per 1,000 patients is
n accurate estimation of what is observed in clinical
ractice in most laboratories with a volume activity of
100 patients/year. Decreasing this risk should be a
riority for the physicians involved in these procedures.
he means by which to recognize, manage, and prevent
omplications during AF ablation have been comprehen-
ively established by Dixit and Marchlinski (17). Al-
hough the occurrence rate of some potentially lethal
omplications, such as atrioesophageal fistula, may de-
rease in the future by implementing advanced innovative
ethods (17), other complications, such as tamponade,
re unlikely to be affected.
Given that cardiac tamponade is the most frequently
bserved complication of AF ablation and the main cause
f procedure-related mortality, it is of paramount impor-
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May 12, 2009:1804–6 Mortality After AF Ablationance that the operators themselves have good experience
n percutaneous pericardiocenthesis or have immediate
ccess to another physician who has mastered these skills
18). In experienced laboratories, a surgical approach was
equired in 14% of cases when percutaneous pericardio-
enthesis failed (19,20). Original nonsurgical techniques
f pericardial drainage have been described by several
nvestigators (21–23), but these techniques are unlikely to
e applicable on a large scale. The Cappato et al. (16)
tudy did not provide information on the availability of
urgical backup for the patients who died due to tam-
onade, precluding the possibility of further elaborating
he role of such backup in a course lethal to the patient.
s such, the question of whether AF ablation procedures
hould only be performed in electrophysiologic centers
here surgical backup is available remains unresolved.
y personal view is that surgical backup is mandatory
nd that it may prevent a lethal outcome in some patients.
tudy limitations. The study of Cappato et al. (16) has
mportant limitations, most of them acknowledged and
ddressed by the authors:
. The data are based on retrospective, volunteer-based
surveys and may underestimate the true prevalence and
nature of events. As stated by the authors (16), mortality
rates in prospective surveys are higher than those of
retrospective studies (24,25), and some fatalities that
were a direct consequence of the procedure but occurred
very late after the procedure may have been unreported.
. No comparison can be made between the mortality rates
reported in the first and second surveys. Taking into
account the number of patients included in each of them,
and assuming that there had been no overlap between the
2 groups, the mortality rate rose from 0.05% in the first
survey to 0.12% in the second one (p  0.07 by Fisher
exact test). Such an increase in mortality rate could be
explained by the inclusion of more difficult cases (chronic
and persistent AF vs. paroxysmal AF) and/or higher-risk
patients (elderly, organic heart disease, cardiac failure,
associated comorbidity). The authors did not provide any
information on the type of AF that was ablated or the
patients’ clinical status.
. The causes of death are only descriptive with no detailed
verification. Possible precipitating causes of the compli-
cations are not provided, for example, the cause of
tamponade or the level of anticoagulation in those
patients with stroke.
. The relevance of sex of the AF patients is not adequately
discussed. Several studies have shown a female preva-
lence of cardiac perforation in patients undergoing per-
cutaneous coronary interventions (26) and catheter abla-
tion of AF (27) and accessory pathways (28). Since there
is a male prevalence in the patient population undergoing
catheter ablation of AF, it would have been interesting
to assess a possible sex difference in the incidence of
complications, especially of tamponade.utchinson and Callans (15) recently recommended the
reation of a procedural registry for AF ablation, similar to
he Society of Thoracic Surgeons National Cardiac Surgery
atabase that has revolutionized our understanding of
oronary artery bypass and valve surgery. The data provided
y the Cappato et al. (16) study should prompt the
nstitution of such registries by both national and interna-
ional electrophysiologic societies.
Can a mortality rate of approximately 1 per 1,000 be
onsidered an “acceptable risk” for a procedure for which the
ain expectation is improvement in quality of life? Al-
hough it is our responsibility to provide all of the facts
bout the risks and benefits of the procedure, it is the
nformed patient who will ultimately decide whether or not
o undergo it. Until the publication of the Cappato et al.
16) study, our patients who were scheduled for AF ablation
ere informed about the relatively low complication rate
ssociated with the procedure. Now, after the publication of
his report, they will be aware of the 1 per 1,000 mortality
ate. It is possible that some of them will prefer alternative
ptions to manage their arrhythmias such as another anti-
rrhythmic drug trial, a rate-control policy, or even a visit to
heir local emergency room. Since AF itself is associated
ith an increased mortality rate (29), only long-term large
andomized trials for comparing mortality following abla-
ion or nonablation therapy of AF will tell whether they had
ecided wisely.
eprint requests and correspondence: Dr. Bernard Belhassen,
epartment of Cardiology, Tel-Aviv Sourasky Medical Center,
eizman Street 6, Tel-Aviv 64239, Israel. E-mail: bblhass@
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